Media stories about TherapeuticsMD (NASDAQ:TXMD) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.625070955777 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of TherapeuticsMD (TXMD) opened at $5.51 on Monday. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30. The stock has a market cap of $1,190.00, a PE ratio of -14.13 and a beta of 0.99.

Several research analysts recently issued reports on TXMD shares. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 25th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. Cowen reiterated an “outperform” rating and issued a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Finally, Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $14.50.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the transaction, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 23.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact TherapeuticsMD (TXMD) Share Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.